Horizon Pharma (NASDAQ:HZNP) Rating Reaffirmed
In a recent report sent to clients and investors this morning, Morgan Stanley has reaffirmed their Underweight rating on Horizon Pharma (NASDAQ:HZNP) shares. The target price indicates a possible upside of 4.40% from firm’s last close price.
From a total of 9 analysts covering Horizon Pharma (NASDAQ:HZNP) stock, 7 rate it a ”Buy”, 0 a “Sell”, and 1 a ”Hold”. This means that 88% of the ratings are positive. The highest target price is $45 while the lowest target price is $31. The mean of all analyst targets is $38.67 with a 73.79% above today’s ($21.29) stock price. Horizon Pharma was the topic of 5 analyst reports since September 9, 2015 according to the firm StockzIntelligence Inc. Jefferies reinitiated shares on November 23 with “Buy” rating. Brean Capital downgraded HZNP stock in a recent report from September 22 to “Hold” rating.
Approximately 1.68 million shares of stock traded hands. Horizon Pharma PLC (NASDAQ:HZNP) has declined 21.66% since April 30, 2015 and is downtrending. It has underperformed by 21.37% the S&P500.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical firm focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The company has a market cap of $3.39 billion. The Firm markets a portfolio of products in arthritis, inflammation and orphan diseases. It currently has negative earnings. The Company’s the United States marketed products are ACTIMMUNE , DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).
According to Zacks Investment Research, “Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNE? (interferon gamma-1b), DUEXIS? (ibuprofen/famotidine), PENNSAID? (diclofenac sodium topical solution) 2% w/w, RAYOS? (prednisone) delayed-release tablets and VIMOVO? (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.” Get a free copy of the Zacks research report on Horizon Pharma PLC (HZNP).